1.
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
by Gaj, Thomas
Trends in biotechnology (Regular ed.), 2013, Vol.31 (7), p.397-405
2.
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers
by Hilton, Isaac B
Nature biotechnology, 2015-05, Vol.33 (5), p.510-517
3.
Increasing the specificity of CRISPR systems with engineered RNA secondary structures
by Kocak, D Dewran
Nature biotechnology, 2019-06, Vol.37 (6), p.657-666
4.
Editing the Epigenome: Reshaping the Genomic Landscape
by Holtzman, Liad
Annual review of genomics and human genetics, 2018-08-31, Vol.19 (1), p.43-71
5.
CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome
by Klann, Tyler S
Nature biotechnology, 2017-06, Vol.35 (6), p.561-568
6.
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
by Nelson, Christopher E
Nature medicine, 2019-03, Vol.25 (3), p.427-432
7.
Jumping at the chance for precise DNA integration
by Kwon, Jennifer B
Nature biotechnology, 2019-09, Vol.37 (9), p.1004-1006
8.
Targeted transcriptional modulation with type I CRISPR–Cas systems in human cells
by Pickar-Oliver, Adrian
Nature biotechnology, 2019-09-23, Vol.37 (12), p.1493-1501
9.
Gene therapies for hemophilia hit the mark in clinical trials
by Pickar, Adrian K
Nature medicine, 2018-02-07, Vol.24 (2), p.121-122
10.
Cas9 loosens its grip on off-target sites
by Nelson, Christopher E
Nature biotechnology, 2016-03, Vol.34 (3), p.298-299
11.
Targeted genome and epigenome editing using engineered TALE and CRISPR/Cas9 technologies
by Gersbach, Charles A
Molecular pain, 2014, Vol.10 (Suppl 1), p.O4-O4
12.
Cas9 loosens its grip on off-target sites: two new variants of the Cas9 nuclease have minimal activity at off-target DNA sites
by Nelson, Christopher E
Nature biotechnology, 2016-03-01, Vol.34 (3), p.298
13.
CRISPR technology for gene therapy
by High, Katherine
Nature medicine, 2014-05, Vol.20 (5), p.476-477
